Mercer Global Advisors
ABUS icon

Mercer Global Advisors’s Arbutus Biopharma ABUS Stock Holding History

Mercer Global Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.1K Sell
19,345
-25,775
-57% -$113K ﹤0.01% 3051
2025
Q4 		$217K Buy
45,120
+6,161
+16% +$27.7K ﹤0.01% 2493
2025
Q3 		$177K Buy
38,959
+3,280
+9% +$12K ﹤0.01% 2418
2025
Q2 		$110K Buy
35,679
+15,179
+74% +$50.4K ﹤0.01% 2148
2025
Q1 		$71.5K Hold
20,500
– – ﹤0.01% 2078
2024
Q4 		$67K Buy
+20,500
New +$75.4K ﹤0.01% 2069

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Mercer Global Advisors's ABUS Position: Q1 2026 in Review

Mercer Global Advisors reduced its Arbutus Biopharma (ABUS) stake by 57% in Q1 2026, selling an estimated $113K and leaving 19,345 shares worth $87.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3051.

Mercer Global Advisors first reported a position in ABUS in Q4 2024 and has held it in 6 quarters since. The position peaked at $217K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Mercer Global Advisors held 19,345 shares of Arbutus Biopharma worth $87.1K as of Q1 2026.
  • Mercer Global Advisors sold 25,775 Arbutus Biopharma shares in Q1 2026, an estimated $113K.
  • Arbutus Biopharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3051 holding.
  • Mercer Global Advisors first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 6 quarters since.
  • Mercer Global Advisors's Arbutus Biopharma position peaked at $217K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.